Theralase Anti-Cancer Technology Research Accepted for Peer Reviewed Publication

Toronto, Ontario  February 3, 2015, Theralase Technologies Inc. ("Theralase") (TLT:TSXV) (TLTFF: OTC Pink(R)), a developer of advanced Photo Dynamic Therapy ("PDT"), for serious and life-threatening diseases, announced today that research on its Anti-Cancer Technology ("ACT") platform involving its lead Photo Dynamic Compound ("PDC") TLD-1433 has been peer reviewed and accepted for publication in the journal Photochemical & Photobiological Sciences.

Results from the preclinical studies of Theralase's PDT entitled, "A novel class of ruthenium-based photosensitizers effectively kills in-vitro cancer cells and in-vivo tumors" has been accepted for publication by the journal of Photochemical & Photobiological Sciences, a society-owned journal publishing high quality research on all aspects of photochemistry and photobiology.

Published: 03 February 2015
Written by Editor
Up on News   Project Update   TSXV  
Read more: Theralase Technologies Inc ( TLT )

Esperion Therapeutics Announces Removal of PPAR Partial Clinical Hold for ETC-1002

Conference Call and Webcast on Monday, February 2, 2015 at 4:30 p.m. Eastern Time

ANN ARBOR, MI--(February 02, 2015) - Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardio-metabolic risk markers, today announced the U.S. Food and Drug Administration (FDA) has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002. The action by the FDA will now allow Esperion to conduct clinical trials exceeding six months in duration.

Published: 03 February 2015
Written by Editor
Nasdaq   FDA HC Decision   Up on News  
Read more: Esperion Therapeutics Inc ( ESPR )

Zogenix Receives FDA Approval of New Formulation of Zohydro(R) ER

Zohydro ER With BeadTek(TM) to be Available in the Second Quarter of 2015

SAN DIEGO, Jan. 30, 2015 -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Zohydro(R) ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek(TM). BeadTek is a formulation technology designed to provide abuse-deterrent properties without changing the release properties of hydrocodone when Zohydro ER is used as intended. Concurrently, Zogenix has ongoing Human Abuse Liability studies, which will further characterize the abuse-deterrent properties of the new formulation. Zogenix intends to submit these data in the second half of 2015 to the FDA to support an amended product label, including abuse-deterrent claims consistent with the FDA's current draft Guidance for Industry, Abuse-Deterrent Opioids -- Evaluation and Labeling.

Published: 30 January 2015
Written by Editor
Nasdaq   Project Update   After Market News  
Read more: Zogenix Inc ( ZGNX )

ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2015 Financial Results

− Conference Call Today at 8:00 am ET−

  • Profit reported for quarter, driven by partner activity; Company reiterates previous financial guidance for fiscal year.

  • Numerous events expected in 2015 with ImmunoGen and partner product programs.

ImmunoGen, Inc. (IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported financial results for the three-month period ended December 31, 2014 – the second quarter of the Company’s 2015 fiscal year (2QFY2015). ImmunoGen also provided an update on product programs and reiterated its financial guidance.

Published: 30 January 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: ImmunoGen Inc ( IMGN )

Spark Therapeutics Announces Pricing of Its Initial Public Offering

PHILADELPHIA, Jan. 30, 2015  -- Spark Therapeutics announced today the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Spark. In addition, Spark has granted the underwriters an option to purchase up to 1,050,000 additional shares of common stock at the public offering price, less the underwriting discount. Spark's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the symbol "ONCE" on January 30, 2015.

Published: 30 January 2015
Written by Editor
Nasdaq   Up on News   New Listing  
Read more: Spark Therapeutics ( ONCE )
  1. CorMedix Inc ( CRMD )
  2. Genetic Technologies Limited ( GENE )
  3. Abiomed Inc ( ABMD )
  4. ProMetic Life Sciences Inc ( PLI )
  5. Actinium Pharmaceuticals Inc ( ATNM )